Advertisement

LH-RH Agonists in the Treatment of Ovarian Cancer

  • G. Emons
  • O. Ortmann
  • G. S. Pahwa
  • F. Oberheuser
  • K.-D. Schulz
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 124)

Abstract

Ovarian carcinoma is one of the most common causes of cancer death in women. During the last decade there have been some advances in surgical, radiation, and cytotoxic chemotherapy of this malignancy. The overall results of these treatments, however, are still disappointing (MRC Gynecologic Cancer Working Party 1990; Averette and Donato 1990; Blackledge and Lawton 1989). Aggressive chemotherapy is burdened with severe acute side effects. In addition, chemotherapy in ovarian cancer is associated with a 4–12 times higher risk of developing leukemia (Kaldor et al. 1990). One trend in modern oncology has been to reduce at least therapy-induced morbidity, if the efficacy of therapy cannot be improved by increased aggressiveness. With breast and endometrial cancer this has been successfully achieved by the introduction of endocrine treatments, both ablative or additive, that take advantage of the sex-steroid dependence of some of these tumors, as reflected by the presence of estrogen and/or progestin receptors (Desombre et al. 1987). Also many ovarian cancers contain significant amounts of sex-steroid receptors. Therapeutic approaches, however, using either antiestrogens or progestins, have not been satisfying (for review, see Desombre et al. 1987; Rao and Slotman 1991).

Keywords

Ovarian Cancer Ovarian Cancer Cell Line Advanced Ovarian Cancer Luteinizing Hormone Release Hormone Human Granulosa Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aten A, Polan ML, Bayless R, Behrman H (1987) A gonadotropin-releasing hormone (GnRH)-like protein in human ovaries: similarity to the GnRH-like ovarian protein of the rat. J Clin Endocrinol Metab 64:1288–1293PubMedCrossRefGoogle Scholar
  2. Averette HE, Donato DM (1990) Ovarian carcinoma, advances in diagnosis, staging and treatment. Cancer 65:703–708PubMedCrossRefGoogle Scholar
  3. Bajusz S, Janaky T, Csernus VJ, Bokser L, Fekete M, Srkalovic G, Redding TW, Schally AV (1989 a) Highly potent metallopeptide analogues of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 86:6313–6317PubMedCrossRefGoogle Scholar
  4. Bajusz S, Janaky T, Csernus VJ, Bokser L, Fekete M, Srkalovic G, Redding TW, Schally AV (1989 b) Highly potent analogues of luteinizing hormone-releasing hormone containing D-phenylalanine nitrogen mustard in position 6. Proc Natl Acad Sci USA 86:6318–6322PubMedCrossRefGoogle Scholar
  5. Bauknecht T, Runge M, Schwall M, Pfleiderer A (1988) Occurrence of epidermal growth factor receptors (EGF-R) in human adnexal tumors and their prognostic value in advanced ovarian carcinomas. Gynecol Oncol 29:147–157PubMedCrossRefGoogle Scholar
  6. Belisle S, Guevin JF, Bellabarba D, Lehoux JG (1984) Luteinizing hormone releasing hormone binds to enriched placental membranes and stimulates in vitro the synthesis of bioactive human chorionic gonadotropin. J Clin Endocrinol Metab 59:119–126PubMedCrossRefGoogle Scholar
  7. Blackledge G, Lawton FG (1989) Second Birmingham gynecological cancer workshop on second line treatment of ovarian cancer. Br J Cancer 59:657–659CrossRefGoogle Scholar
  8. Blankenstein MA, Henkelman MS, Klijn JGM (1985) Direct inhibitory effect of a luteinizing hormone-releasing hormone agonist on MCF-7 human breast cancer cells. Eur J Cancer Clin Oncol 21:1493–1499PubMedCrossRefGoogle Scholar
  9. Bramley TA, Menzies GS, Baird DT (1985) Specific binding of gonadotropin-releasing hormone and an agonist to human corpus luteum homogenates: characterization, properties and luteal phase levels. J Clin Endocrinol Metab 61:834–841PubMedCrossRefGoogle Scholar
  10. Bruckner HW, Motwani BT (1989) Treatment of advanced refractory ovarian carcinoma with a gonadotropin-releasing hormone analogue. Am J Obstet Gynecol 161:1216–1218PubMedGoogle Scholar
  11. Bützow R, Huhtaniemi I, Clayton R, Wahlström T, Andersson LC, Seppälä M (1987) Cultured mammary carcinoma cells contain gonadotropin releasing hormone-like im-munoreactivity, GnRH binding sites and chorionic gonadotropin. Int J Cancer 39:498–501PubMedCrossRefGoogle Scholar
  12. Casagrande JT, Louie EW, Pike MC, Roy S, Rock RK, Henderson BE (1979) Incessant ovulation and ovarian cancer? Lancet 2:170–173PubMedCrossRefGoogle Scholar
  13. Casper RF, Erickson GF, Rebar RW, Yen SSC (1982) The effect of luteinizing hormone-releasing factor and its agonist on cultured human granulosa cells. Fertil Steril 37:406–409PubMedGoogle Scholar
  14. Clayton RN, Huhtaniemi I (1982) Absence of gonadotropin-releasing hormone receptors in human gonadal tissue. Nature 299:56–59PubMedCrossRefGoogle Scholar
  15. Cramer DW, Welch WR (1983) Determinants of ovarian cancer risk: II. Inferences regarding pathogenesis. JNCI 71:717–721PubMedGoogle Scholar
  16. Currie AJ, Fraser HM, Sharpe RM (1981) Human placental receptors for luteinizing hormone releasing hormone. Biochem Biophys Res Commun 89:332–338CrossRefGoogle Scholar
  17. Desombre ER, Holt JA, Herbst AC (1987) Steroid receptors in breast, uterine and ovarian malignancy. In: Gold JJ, Josinovich JB (eds) Gynecologic endocrinology. Plenum, New York, pp 511–528CrossRefGoogle Scholar
  18. Eidne KA, Flanagan CA, Harris NS, Millar RP (1987) Gonadotropin-releasing hormone (GnRH)-binding sites in human breast cancer cell Unes and inhibitory effects of GnRH-antagonists. J Clin Endocrinol Metab 64:425–432PubMedCrossRefGoogle Scholar
  19. Emons G, Pahwa GS, Brack C, Sturm R, Oberheuser F, Knuppen R (1989) Gonadotropin-releasing hormone binding sites in human epithelial ovarian carcinomata. Eur J Cancer Clin Oncol 25:215–221PubMedCrossRefGoogle Scholar
  20. Emons G, Pahwa GS, Sturm R, Knuppen R, Oberheuser F (1990) The use of GnRH analogues in ovarian cancer. In: Vickery BH, Lunenfeld B (eds) GnRH analogues in cancer and human reproduction, vol 3. Kluwer, dordrecht, pp 159–170CrossRefGoogle Scholar
  21. Fathalla MF (1971) Incessant ovulation — a factor in ovarian neoplasia? Lancet 2:163PubMedCrossRefGoogle Scholar
  22. Fekete M, Bajusz S, Groot K, Csernus VJ, Schally AV (1989 a) Comparison of different agonists and antagonists of luteinizing hormone-releasing hormone for receptor-binding ability to rat pituitary and human breast cancer membranes. Endocrinology 124:946–955PubMedCrossRefGoogle Scholar
  23. Fekete M, Zalatnai A, Comaru-Schally AM, Schally AV (1989 b) Membrane receptors for peptides in experimental and human pancreatic cancers. Pancreas 4:521–528PubMedCrossRefGoogle Scholar
  24. Freedman RS, Saul PS, Edwards CL, Jolies CJ, Gershenson DM, Jones LA, Atkinson EN, Dana WJ (1986) Ethinyl estradiol and medroxyprogesterone acetate in patients with epithelial ovarian carcinoma: a phase II study. Cancer Treat Rep 70:369–373PubMedGoogle Scholar
  25. Hofmann J, Hölzel F, Hackenberg R, Schulz KD (1989) Characterization of epidermal growth-factor related proteins from human urinary chorionic gonadotropin. J Endocrinol 123:333–340PubMedCrossRefGoogle Scholar
  26. Hsueh AJW, Schaeffer M (1985) Gonadotropin-releasing hormone as a paracrine hormone and neurotransmitter in extrapituitary sites. J Steroid Biochem 23:757–764PubMedCrossRefGoogle Scholar
  27. Iwashita M, Evans MI, Catt KJ (1986) Characterization of a gonadotropin-releasing hormone receptor site in term placenta and chorionic villi. J Clin Endocrinol Metab 62:127–133PubMedCrossRefGoogle Scholar
  28. Jäger W, Wildt L, Lang N (1989) Some observations on the effects of a GnRH analog in ovarian cancer. Eur J Obstet Gynecol Reprod Biol 32:137–148PubMedCrossRefGoogle Scholar
  29. Kaldor JM, Day NE, Petterson F, Clarke EA, Pedersen D, Mehnert W, Bell J, Host H, Prior P, Karjalainen S, Neal F, Koch M, Band P, Choi W, Kirn VP, Arslan A, Zarén B, Belch AR, Storm H, Kittelmann B, Fraser P, Stovall M (1990) Leukemia following chemotherapy for ovarian cancer. N Engl J Med 322:1–6PubMedCrossRefGoogle Scholar
  30. Kammerman S, Demopoulos RI, Raphael C, Ross J (1981) Gonadotropic hormone binding to human ovarian tumors. Hum Pathol 12:886–890PubMedCrossRefGoogle Scholar
  31. Kauppila A, Martikainen H, Pentinen J, Reinilä M (1990) GnRH-agonist analogue treatment of ovarian granulosa cell malignancies. Gynecol Endocrinol 4 [Suppl 2]:97Google Scholar
  32. Kavanagh JJ, Roberts W, Townsend P, Hewitt S (1989) Leuprolide acetate in the treatment of refractory or persistent epithelial ovarian cancer. J Clin Oncol 7:115–118PubMedGoogle Scholar
  33. Knecht M, Ranta T, Feng P, Shinohara O, Catt KJ (1985) Gonadotropin-releasing hormone as a modulator of ovarian function. J Steroid Biochem 23:771–778PubMedCrossRefGoogle Scholar
  34. Kullander S, Rausing A, Schally AV (1987) LH-RH agonist treatment in ovarian cancer. In: Klijn JGM (ed) Hormonal manipulation of cancer: peptides, growth factors and new (anti) steroidal agents. Raven, New York, pp 353–356Google Scholar
  35. Kvale G, Heuch J, Nüssen S, Beral V (1988) Reproductive factors and risk of ovarian cancer: a prospective study. Int J Cancer 42:246–251PubMedCrossRefGoogle Scholar
  36. Lamberts SWJ, Timmers JM, Oosterom R, Verleun T, Rommerts FG, de Jong FH (1982) Testosterone secretion by cultured arrhenoblastoma cells: suppression by a luteinizing hormone-releasing hormone agonist. J Clin Endocrinol Metab 54:450–454PubMedCrossRefGoogle Scholar
  37. Latouche J, Crumeyrolle-Arias M, Jordan D, Kopp N, Augendre-Ferrante B, Cedard L, Haour F (1991) GnRH receptors in human granulosa cells: anatomical localization and characterization by autoradiographic study. Endocrinology 125:1739–1741CrossRefGoogle Scholar
  38. Lee MT, Liebow C, Kramer AR, Schally AV (1991) Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphoryla-tion and dephosphorylation of tyrosine residues of specific protein substrates in various tumors. Proc Natl Acad Sci USA 88:1656–1660PubMedCrossRefGoogle Scholar
  39. Levy J, Segal T, Wiznitzer A, Insler V, Sharoni Y (1989) Molecular mechanisms of GnRH action on mammary tumors and uterine leiomyomata. In: Vickery BH, Lunenfeld B (eds) GnRH-Analogues in cancer and human reproduction, vol 1. Kluwer, Dordrecht, pp 127–136Google Scholar
  40. Li CH, Ramasharma K, Yamashiro D, Chung D (1987) Gonadotropin-releasing peptide from human follicular fluid: isolation, characterization and chemical synthesis. Proc Natl Acad Sci USA 86:959–962CrossRefGoogle Scholar
  41. Mayer A (1925) Klinik der Ovarialtumoren, Ätiologie. In: Halban J, Seitz L (eds) Biologie und Pathologie des Weibes, vol 5, part 2. Urban und Schwarzenberg, München, pp 877–881Google Scholar
  42. Miller WR, Scott WN, Morris R, Fraser HM, Sharpe RM (1985) Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature 313:231–233PubMedCrossRefGoogle Scholar
  43. Mortel R, Satyaswaroop PG, Schally AV, Hamilton T, Ozols R (1986) Inhibitory effect of GnRH superagonist on the growth of human ovarian carcinoma NIH: OVCAR 3 in the nude mouse. Gynecol Oncol 23:254–255CrossRefGoogle Scholar
  44. MRC Gynecologic Cancer Working Party (1990) An overview in the treatment of advanced ovarian cancer. Br J Cancer 61:495–496CrossRefGoogle Scholar
  45. Mullen P, Scott WN, Miller WR (1991) Growth inhibition observed following administration of an LH-RH agonist to a clonal variant of the MCF-7 breast cancer cell line is accompanied by an accumulation of cells in the G0/G1 phase of the cell cycle. Br J Cancer 63:930–932PubMedCrossRefGoogle Scholar
  46. Nakano R, Kitayama S, Yamoto M, Ooshima A (1989) Localization of gonadotropin binding sites in human ovarian neoplasms. Am J Obstet Gynecol 161:905–910PubMedGoogle Scholar
  47. Naor Z (1990) Signal transduction mechanisms of Ca2+ mobilizing hormones: the case of gonadotropin-releasing hormone. Endocr Rev 11:326–353PubMedCrossRefGoogle Scholar
  48. Ohtani K (1990) Effects of gonadotropin on the growth of malignant ovarian neoplasms assessed by subrenal capsule assay. Nippon Sanka Fujinka Gakki Zasshi 42:579–585Google Scholar
  49. Ohtani K, Sakamoto H, Konbai D (1990) Antagonistic effects of GnRH agonist on gonadotropin stimulated proliferation of human ovarian cancer cell line. Gynecol En-docrinol 4 (Suppl 2):98Google Scholar
  50. Olshausen R (1877) Die Krankheiten der Ovarien, Ätiologie. In: Billroth T (ed) Handbuch der Frauenkrankheiten, vol 6. Enke, Stuttgart, pp 74–78Google Scholar
  51. Olsson JH, Akesson I, Hillensjoe T (1990) Effects of a gonadotropin-releasing hormone agonist on progesterone formation in cultured human granulosa cells. Acta Endocrinol (Copenh) 122:427–431Google Scholar
  52. Pahwa GS, Vollmer G, Knuppen R, Emons G (1989) Photoaffinity labelling of gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata. Biochem Biophys Res Commun 161:1086–1092PubMedCrossRefGoogle Scholar
  53. Pahwa GS, Kullander S, Vollmer G, Oberheuser F, Knuppen R, Emons G (1991) Specific low affinity binding sites for gonadotropin releasing hormone in human endometrial carcinomata. Eur J Obstet Gynecol Reprod Biol 41:135–142PubMedCrossRefGoogle Scholar
  54. Parmar H, Nicoll J, Stockdale A, Cassoni A, Phillips RH, Lightman SL, Schally AV (1985) Advanced ovarian carcinoma: response to the agonist D-Trp6-LH-RH. Cancer Treat Rep 69:1341–1342PubMedGoogle Scholar
  55. Parmar H, Phillips RH, Rustin F, Lightman SL, Hanham JW, Schally AV (1988 a) Therapy of advanced ovarian cancer with D-Trp6-LH-RH (decapeptyl) microcapsules. Biomed Pharmacother 42:531–538PubMedGoogle Scholar
  56. Parmar H, Rustin F, Lightman SL, Phillips RH, Hanham JW, Schally AV (1988 b) Response to D-Trp6-luteinizing hormone releasing hormone (Decapeptyl) microcapsules in advanced ovarian cancer. B M J 296:1229CrossRefGoogle Scholar
  57. Pellicer A, Mirô F (1990) Steroidogenesis in vitro of human granulosa-luteal cells pretreated in vivo with gonadotropin-releasing hormone analogs. Fertil Steril 54:590–596PubMedGoogle Scholar
  58. Peterson CM, Zimniski SJ (1990) A long acting gonadotropin-releasing hormone agonist inhibits the growth of a human ovarian epithelial carcinoma (BG-1) heterotransplanted in the nude mouse. Obstet Gynecol 76:264–267PubMedGoogle Scholar
  59. Petraglia F, Vaughan J, Vale W (1990) Steroid hormones modulate the release of immunore-active gonadotropin-releasing hormone from cultured human placental cells. J Clin Endocrinol Metab 70:1173–1178PubMedCrossRefGoogle Scholar
  60. Popkin R, Bramley TA, Currie A, Shaw RW, Baird DT, Fraser HM (1983) Specific binding of luteinizing hormone-releasing hormone to human luteal tissue. Biochem Biophys Res Commun 114:750–756PubMedCrossRefGoogle Scholar
  61. Pour PM, Redding TW, Paz-Bouza JI, Schally AV (1988) Treatment of experimental ovarian carcinoma with monthly injection of the agonist D-Trp6-LH-RH: a preliminary report. Cancer Lett 41:105–110PubMedCrossRefGoogle Scholar
  62. Qayum A, Gullick W, Clayton RC, Sikora K, Waxman J (1990 a) The effects of gonadotropin-releasing hormone analogues in prostate cancer are mediated through specific tumour receptors. Br J Cancer 62:96–99PubMedCrossRefGoogle Scholar
  63. Qayum A, Gullick WJ, Mellon K, Krausz T, Neal D, Sikora K, Waxman J (1990 b) The partial purification and characterization of the GnRH-like activity from prostatic biopsy specimens and prostatic cancer cell lines. J Steroid Biochem Mol Biol 37:899–902PubMedCrossRefGoogle Scholar
  64. Radovick S, Wondisford FE, Nakayama Y, Yamada M, Cutler GB Jr, Weintraub BD (1990) Isolation and characterization of the human gonadotropin-releasing hormone gene in the hypothalamus and placenta. Mol Endocrinol 4:476–480PubMedCrossRefGoogle Scholar
  65. Rajaniemi H, Kauppila A, Rönnberg L, Selander K, Pystynen P (1981) LH (hCG) receptor in benign and malignant tumors of human ovary. Acta Obstet Gynecol Scand Suppl 101:83–86PubMedCrossRefGoogle Scholar
  66. Rao BR, Slotman BJ (1991) Endocrine factors in common epithelial ovarian cancer. Endocr Rev 12:14–26PubMedCrossRefGoogle Scholar
  67. Scambia G, Panici PB, Baiocchi G, Perrone L, Gaggini G, Iacobelli S, Mancuso S (1988) Growth inhibitory effect of LH-RH analogs on human breast cancer cells. Anticancer Res 8:187–190PubMedGoogle Scholar
  68. Schlesselman JJ (1989) Cancer of the breast and reproductive tract in relation to use of oral contraceptives. Contraception 40:1–38PubMedCrossRefGoogle Scholar
  69. Seppälä M, Wahlström R (1980) Identification of luteinizing hormone releasing factor and a-subunit of glycoprotein hormones in ductal carcinoma of the mammary gland. Int J Cancer 26:231–233CrossRefGoogle Scholar
  70. Siler-Khodr TM, Khodr GS (1980) Placental luteinizing hormone releasing factor and its synthesis. Science 207:315–317PubMedCrossRefGoogle Scholar
  71. Simon WE, Hölzel F (1979) Hormone sensitivity of gynecological tumor cells in tissue cultures. J Cancer Res Clin Oncol 94:307–323PubMedCrossRefGoogle Scholar
  72. Simon WE, Albrecht M, Hansel M, Dietl M, Hölzel F (1983) Cell lines derived from human ovarian carcinomas: growth stimulation by gonadotropic and steroid hormones. JNCI 70:839–845PubMedGoogle Scholar
  73. Slotman BJ, Poels LG, Rao BR (1989) A direct LH-RH-agonist action on cancer cells is unlikely to be the cause of response to LH-RH-agonist treatment. Anticancer Res 9:77–80PubMedGoogle Scholar
  74. Srkalovic G, Wittliff JL, Schally AV (1990) Detection and partial characterization of receptors for [D-Trp6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma. Cancer Res 50:1841–1846. Erratum published in: Cancer Res 50:3808PubMedGoogle Scholar
  75. Stadel BV (1975) The etiology and prevention of ovarian cancer. Am J Obstet Gynecol 123:772–774PubMedGoogle Scholar
  76. Stouffer RL, Grodin MS, Davis JR, Surwitt EA (1984) Investigation of binding sites for follicle-stimulating hormone and ehorionic gonadotropin in human ovarian cancers. J Clin Endocrinol Metab 59:441–446PubMedCrossRefGoogle Scholar
  77. Tan GJS, Biggs JSG (1983) Absence of effect of LH-RH on progesterone production by human luteal cells in vitro. J Reprod Fertil 67:411–413PubMedCrossRefGoogle Scholar
  78. Thompson MA, Adelson MD, Kaufman LM (1991) Lupron retards proliferation of ovarian epithelial tumor cells cultured in serum-free medium. J Clin Endocrinol Metab 72:1036–1041PubMedCrossRefGoogle Scholar
  79. Tureck RW, Mastroianni L Jr, Blasco L, Strauß JF III (1982) Inhibition of human granulosa cell progesterone secretion by a gonadotropin-releasing hormone agonist. J Clin Endocrinol Metab 54:1078–1080PubMedCrossRefGoogle Scholar
  80. Wilding C, Chen M, Gelman EP (1987) LH-RH agonists and human breast cancer cells. Nature 329:770PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • G. Emons
    • 1
    • 2
  • O. Ortmann
    • 1
    • 2
  • G. S. Pahwa
    • 2
  • F. Oberheuser
    • 2
  • K.-D. Schulz
    • 1
  1. 1.Zentrum für Frauenheilkunde und GeburtshilfePhilipps-Univesität MarburgMarburgGermany
  2. 2.Klinik für Frauenheilkunde und GeburtshilfeMedizinische Universität LübeckLübeckGermany

Personalised recommendations